Gedeon Richter

Company snapshot

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.7bn and sales of EUR 2.2bn in 2024, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and G

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Gedeon Richter. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Gedeon Richter.

1. Jun 8, 2026 Clinical update

   RGH-MD-20 — Phase 3

2. Jun 8, 2026 Clinical update

   RGH-188-203 — Phase 3

View all clinical trial activity →

• What is Gedeon Richter?

  Gedeon Richter is a pharma organization headquartered in Budapest, EU. Primary therapeutic focus areas include Adolescent Patients (13 to 17 years of age) with Schizophrenia, Adolescent patient (13-17 years of age) with Schizophrenia. NovaPharmaNews links 2 clinical program(s), 0

• Is Gedeon Richter publicly traded?

  Gedeon Richter appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Gedeon Richter develop or market?

  We link 5 drug profile(s) where Gedeon Richter is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/gedeon-richter-plc#company-drugs.

• What are the latest developments for Gedeon Richter?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Gedeon Richter focus on?

  Gedeon Richter focuses on Adolescent Patients (13 to 17 years of age) with Schizophrenia, Adolescent patient (13-17 years of age) with Schizophrenia based on our analysis of their pipeline programs and drug development activities.